SEC Form 3 · accession 0000899243-18-007410
Arcus Biosciences, Inc. · RCUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer Jarrett
Officer — See Remarks
Period of report
Mar 14, 2018
Accepted (ET)
Mar 14, 2018 · 5:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001724521
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 100,026 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.23 | holding | — | — | — | — | Mar 14, 2017 | Common Stock | 181,166 | — | D |
| Stock Option (right to buy)F2 | $5.39 | holding | — | — | — | — | Jan 3, 2028 | Common Stock | 107,694 | — | D |
Explanation of responses
- F1The option is exercisable in 48 equal monthly installments after March 1, 2017 provided the reporting person remains in continuous service on each vesting date; the option may also be exercised early subject to Issuer's right of repurchase.
- F2The option is exercisable in 48 equal monthly installments after January 1, 2018 provided the reporting person remains in continuous service on each vesting date; the option may also be exercised early subject to Issuer's right of repurchase.
Remarks
Chief Financial Officer and Chief Business Officer